
Diane Nugent Or Diane J Nugent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2926152/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12690.	1.0	37
2	Safety and effectiveness of recombinant factor XIIIâ€A2 in congenital factor XIII deficiency: Realâ€world evidence. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12628.	1.0	3
3	Evidence of a disability paradox in patientâ€reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	1.0	25
4	Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances, 2021, 5, 1617-1626.	2.5	11
5	Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients. Pediatric Infectious Disease Journal, 2021, 40, 606-611.	1.1	5
6	#12: The Safety and antibody kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S7-S7.	0.6	0
7	Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia, 2021, 27, 769-782.	1.0	15
8	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 113, 1-6.	1.5	11
9	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	0.7	21
10	Hemophilia – Impact of Recent Advances on Management. Indian Journal of Pediatrics, 2020, 87, 134-140.	0.3	3
11	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	1.0	54
12	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	0.6	34
13	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	2.5	57
14	High-grade heart block requiring transvenous pacing associated with multisystem inflammatory syndrome in children during the COVID-19 pandemic. HeartRhythm Case Reports, 2020, 6, 811-814.	0.2	14
15	Promising biomarkers for the prediction of catheterâ€related venous thromboembolism in hospitalized children: An exploratory study. Pediatric Blood and Cancer, 2019, 66, e27870.	0.8	4
16	Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875.	1.0	8
17	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	1.8	22
18	Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes. Journal of Pediatric Hematology/Oncology, 2018, 40, e319-e322.	0.3	6

#	Article	IF	CITATIONS
19	PP111 Toward Healthy Coagulation In Hemophilia. International Journal of Technology Assessment in Health Care, 2018, 34, 108-108.	0.2	Ο
20	Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review. Journal of Blood Medicine, 2018, Volume 9, 185-192.	0.7	35
21	Value of prophylaxis vs onâ€demand treatment: Application of a value framework in hemophilia. Haemophilia, 2018, 24, 755-765.	1.0	20
22	Platelet genomics: the role of platelet size and number in health and disease. Platelets, 2017, 28, 27-33.	1.1	5
23	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. Seminars in Thrombosis and Hemostasis, 2017, 43, 059-068.	1.5	15
24	OP16 A Patient-centered Value Framework For Healthcare In Hemophilia. International Journal of Technology Assessment in Health Care, 2017, 33, 8-9.	0.2	1
25	Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 1055-1063.	2.0	6
26	Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia. Seminars in Hematology, 2016, 53, S70-S72.	1.8	16
27	Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency. Journal of Clinical Immunology, 2016, 36, 725-732.	2.0	19
28	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	0.5	46
29	Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the <i>ITGA2B</i> and <i>ITGB3</i> Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.	1.1	67
30	Successful treatment of secondary graft failure following unrelated cord blood transplant with hematopoietic growth factors in a pediatric patient with <scp>F</scp> anconi anemia. Pediatric Transplantation, 2015, 19, E181-4.	0.5	3
31	Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Preference and Adherence, 2015, 9, 1549.	0.8	91
32	Identification of Patients with RAG Mutations Previously Diagnosed with Common Variable Immunodeficiency Disorders. Journal of Clinical Immunology, 2015, 35, 119-124.	2.0	70
33	Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments. The Application of Clinical Genetics, 2014, 7, 55.	1.4	112
34	Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children. Journal of Pediatrics, 2014, 165, 600-605.e4.	0.9	49
35	Psychosocial outcomes of siblings of pediatric stem cell transplant survivors Journal of Clinical Oncology, 2014, 32, 9528-9528.	0.8	0
36	Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia. Pediatric Transplantation, 2013, 17, E104-7.	0.5	7

#	Article	IF	CITATIONS
37	Successful cord blood transplantation in a patient with malignant infantile osteopetrosis and hemophilia. Pediatric Transplantation, 2013, 17, E20-4.	0.5	6
38	Safe and Effective Use Of Romiplostim and Eltrombopag In Children With ITP. Blood, 2013, 122, 3541-3541.	0.6	2
39	Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency. Blood, 2013, 122, 3613-3613.	0.6	0
40	Rare factor deficiencies. Current Opinion in Hematology, 2012, 19, 380-384.	1.2	4
41	X-linked Hyper IgM Syndrome. Journal of Pediatric Hematology/Oncology, 2012, 34, e212-e214.	0.3	5
42	Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood, 2012, 119, 5111-5117.	0.6	116
43	Corifactâ,,¢/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thrombosis Research, 2012, 130, S12-S14.	0.8	40
44	Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload. Pediatric Transplantation, 2012, 16, E69-73.	0.5	18
45	Inflammatory polyps following successful HLAâ€matched cord blood transplantation in a patient with Xâ€linked lymphoproliferative syndrome. Pediatric Transplantation, 2012, 16, E188-91.	0.5	0
46	A Patient With Familial Bone Marrow Failure and an Inversion of Chromosome 8. Journal of Pediatric Hematology/Oncology, 2011, 33, 626-627.	0.3	0
47	Monozygotic Twin Pair Showing Discordant Phenotype for X-linked Thrombocytopenia and Wiskott–Aldrich Syndrome: a Role for Epigenetics?. Journal of Clinical Immunology, 2011, 31, 773-777.	2.0	30
48	Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. British Journal of Haematology, 2009, 146, 585-596.	1.2	230
49	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	13.9	1,681
50	Cytokine Response and Genotype Frequencies in ITP of Childhood Blood, 2007, 110, 569-569.	0.6	0
51	Evidence for the benefits of prophylaxis in the management of hemophilia A. Thrombosis and Haemostasis, 2006, 96, 433-440.	1.8	56
52	The Effect of Antiplatelet Autoantibodies on Megakaryocytopoiesis. International Journal of Hematology, 2005, 81, 94-99.	0.7	61
53	Sensitivity and Efficacy in Measurement of Anti-Platelet Medications Blood, 2005, 106, 1253-1253.	0.6	4
54	Comparison of Three Different Platelet Function Assays to Determine Aspirin Sensitivity Blood, 2004, 104, 3901-3901.	0.6	7

#	Article	IF	CITATIONS
55	PFA-100â,,¢ System: A New Method for Assessment of Platelet Dysfunction. Seminars in Thrombosis and Hemostasis, 1998, 24, 195-202.	1.5	415
56	Molecular Specificity of Anti-IIb/IIIa Human Antibodies. Seminars in Thrombosis and Hemostasis, 1995, 21, 60-67.	1.5	5
57	Isolation and characterization of the α and β chains of human platelet glycoprotein Ib. Biochemical and Biophysical Research Communications, 1987, 147, 526-534.	1.0	20
58	Hemorrhage Involving the Upper Airway in Hemophilia. Clinical Pediatrics, 1986, 25, 436-439.	0.4	12